Etazolate

Etazolate
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name Ethyl 1-ethyl-4-[2-(propan-2-ylidene)hydrazinyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate;
CAS Number	51022-77-6;
PubChem CID	3277;
IUPHAR/BPS	7336;
ChemSpider	3162;
UNII	I89Y79062L;
ChEBI	CHEBI:138502;
ChEMBL	ChEMBL356388;
CompTox Dashboard (EPA)	DTXSID4048434 ;
Chemical and physical data
Formula	C14H19N5O2
Molar mass	289.339 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC;
	InChI InChI=1S/C14H19N5O2/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2/h7-8H,5-6H2,1-4H3,(H,15,18); Key:OPQRBXUBWHDHPQ-UHFFFAOYSA-N;

Etazolate (SQ-20,009, EHT-0202) is an anxiolytic drug which is a pyrazolopyridine derivative and has unique pharmacological properties.^[1]^[2]^[3] It acts as a positive allosteric modulator of the GABA_A receptor at the barbiturate binding site,^[4]^[5]^[6]^[7] as an adenosine antagonist of the A₁ and A₂ subtypes,^[8] and as a phosphodiesterase inhibitor selective for the PDE4 isoform.^[9]^[10]^[11] It is currently in clinical trials for the treatment of Alzheimer's disease.^[12]

References

^ Hall JA, Morton I (1999). Concise dictionary of pharmacological agents: properties and synonyms. Kluwer Academic. ISBN 0-7514-0499-3.
^ Williams M (May 1983). "Anxioselective anxiolytics". Journal of Medicinal Chemistry. 26 (5): 619–628. doi:10.1021/jm00359a001. PMID 6132997.
^ Williams M, Risley EA (February 1979). "Enhancement of the binding of 3H-diazepam to rat brain membranes in vitro by SQ 20009, A novel anxiolytic, gamma-aminobutyric acid (GABA) and muscimol". Life Sciences. 24 (9): 833–841. doi:10.1016/0024-3205(79)90367-9. PMID 449623.
^ Zezula J, Slany A, Sieghart W (April 1996). "Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits". European Journal of Pharmacology. 301 (1–3): 207–214. doi:10.1016/0014-2999(96)00066-0. PMID 8773466.
^ Davies MF (1996). "The Pharmacology of the Gamma-Aminobutyric Acid System". In Remington G, Baskys A (eds.). Brain mechanisms and psychotropic drugs. Boca Raton: CRC Press. ISBN 0-8493-8386-2.
^ Olsen RW, Gordey M (2000). "GABAA Receptor Chloride Ion Channels". In Mishina M, Kurachi Y (eds.). Pharmacology of ionic channel function: activators and inhibitors. Handbook of Experimental Pharmacology. Vol. 147. Berlin: Springer. pp. 499–517. doi:10.1007/978-3-642-57083-4_19. ISBN 3-540-66127-1.
^ Olsen RW (1987). "GABA-Drug Interactions". In Jucker E (ed.). Progress in Drug Research. Vol. 31. Boston: Birkhauser. p. 526. ISBN 3-7643-1837-6.
^ Williams M, Jarvis MF (February 1988). "Adenosine antagonists as potential therapeutic agents". Pharmacology, Biochemistry, and Behavior. 29 (2): 433–441. doi:10.1016/0091-3057(88)90182-7. PMID 3283781. S2CID 35635747.
^ Chasin M, Harris DN, Phillips MB, Hess SM (September 1972). "1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)--a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases". Biochemical Pharmacology. 21 (18): 2443–2450. doi:10.1016/0006-2952(72)90414-5. PMID 4345859.
^ Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM (May 1997). "Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D". Biochemical and Biophysical Research Communications. 234 (2): 320–324. doi:10.1006/bbrc.1997.6636. PMID 9177268.
^ Daniel JL (2002). "Platelet signalling; cAMP and cGMP". In Gresele P (ed.). Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology and therapeutics. Cambridge, UK: Cambridge University Press. ISBN 0-521-80261-X.
^ "EHT 0202". Pipeline. ExonHit. Archived from the original on 2011-01-11.

[isbn0-7514-0499-3-1] Hall JA, Morton I (1999). Concise dictionary of pharmacological agents: properties and synonyms. Kluwer Academic. ISBN 0-7514-0499-3.

[pmid6132997-2] Williams M (May 1983). "Anxioselective anxiolytics". Journal of Medicinal Chemistry. 26 (5): 619–628. doi:10.1021/jm00359a001. PMID 6132997.

[pmid449623-3] Williams M, Risley EA (February 1979). "Enhancement of the binding of 3H-diazepam to rat brain membranes in vitro by SQ 20009, A novel anxiolytic, gamma-aminobutyric acid (GABA) and muscimol". Life Sciences. 24 (9): 833–841. doi:10.1016/0024-3205(79)90367-9. PMID 449623.

[pmid8773466-4] Zezula J, Slany A, Sieghart W (April 1996). "Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits". European Journal of Pharmacology. 301 (1–3): 207–214. doi:10.1016/0014-2999(96)00066-0. PMID 8773466.

[isbn0-8493-8386-2-5] Davies MF (1996). "The Pharmacology of the Gamma-Aminobutyric Acid System". In Remington G, Baskys A (eds.). Brain mechanisms and psychotropic drugs. Boca Raton: CRC Press. ISBN 0-8493-8386-2.

[isbn3-540-66127-1-6] Olsen RW, Gordey M (2000). "GABAA Receptor Chloride Ion Channels". In Mishina M, Kurachi Y (eds.). Pharmacology of ionic channel function: activators and inhibitors. Handbook of Experimental Pharmacology. Vol. 147. Berlin: Springer. pp. 499–517. doi:10.1007/978-3-642-57083-4_19. ISBN 3-540-66127-1.

[isbn3-7643-1837-6-7] Olsen RW (1987). "GABA-Drug Interactions". In Jucker E (ed.). Progress in Drug Research. Vol. 31. Boston: Birkhauser. p. 526. ISBN 3-7643-1837-6.

[pmid3283781-8] Williams M, Jarvis MF (February 1988). "Adenosine antagonists as potential therapeutic agents". Pharmacology, Biochemistry, and Behavior. 29 (2): 433–441. doi:10.1016/0091-3057(88)90182-7. PMID 3283781. S2CID 35635747.

[pmid4345859-9] Chasin M, Harris DN, Phillips MB, Hess SM (September 1972). "1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)--a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases". Biochemical Pharmacology. 21 (18): 2443–2450. doi:10.1016/0006-2952(72)90414-5. PMID 4345859.

[pmid9177268-10] Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM (May 1997). "Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D". Biochemical and Biophysical Research Communications. 234 (2): 320–324. doi:10.1006/bbrc.1997.6636. PMID 9177268.

[isbn0-521-80261-X-11] Daniel JL (2002). "Platelet signalling; cAMP and cGMP". In Gresele P (ed.). Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology and therapeutics. Cambridge, UK: Cambridge University Press. ISBN 0-521-80261-X.

[urlPipeline_|_ExonHit-12] "EHT 0202". Pipeline. ExonHit. Archived from the original on 2011-01-11.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

Etazolate

See also

References

Read other articles:

Miss Arizona Teen USA

Halte Dongkelan

List of United Nations organizations

قوائم الفرق في بطولة العالم للأندية 2000

Fakultas Peternakan Universitas Brawijaya

Bündnerfleisch

قرية بروك (نيويورك)

قرية وايتهال (نيويورك)

Daftar Perdana Menteri Belize

DMCA's Sky

Matres and Matronae

LATAM Paraguay

Stadion Schützenwiese

Diskografi Austin Mahone

Puerto Maldonado

Синелобый амазон

المسجد النبوي (قزوين)

Made (TV series)

Untash-Napirisha

Виртус